Cargando…
SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)
OBJECTIVE: To study the association between insulin receptors (isoforms α and β), insulin growth factor‐1 (IGF1) and serine/arginine splicing factor 1 (SRSF‐1) in patients with prostate cancer (PC) and diabetes. MATERIALS AND METHODS: We retrospectively analyzed data from 368 patients who underwent...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362056/ https://www.ncbi.nlm.nih.gov/pubmed/34196424 http://dx.doi.org/10.1002/pros.24185 |
_version_ | 1783738076949905408 |
---|---|
author | Broggi, Giuseppe Lo Giudice, Arturo Di Mauro, Marina Asmundo, Maria Giovanna Pricoco, Elisabetta Piombino, Eliana Caltabiano, Rosario Morgia, Giuseppe Russo, Giorgio Ivan |
author_facet | Broggi, Giuseppe Lo Giudice, Arturo Di Mauro, Marina Asmundo, Maria Giovanna Pricoco, Elisabetta Piombino, Eliana Caltabiano, Rosario Morgia, Giuseppe Russo, Giorgio Ivan |
author_sort | Broggi, Giuseppe |
collection | PubMed |
description | OBJECTIVE: To study the association between insulin receptors (isoforms α and β), insulin growth factor‐1 (IGF1) and serine/arginine splicing factor 1 (SRSF‐1) in patients with prostate cancer (PC) and diabetes. MATERIALS AND METHODS: We retrospectively analyzed data from 368 patients who underwent surgery for PC or benign prostatic hyperplasia (BPH) between 2010 and 2020 at the Department of Urology, University of Catania. Tissue microarray slides were constructed and they were stained for androgen receptor (AR), insulin receptor‐α and ‐β, IGF1 (IGF1‐R), Ki‐67, and prostate specific membrane antigen (PSMA) expression using validated score. RESULTS: The final cohort was represented by 100 patients with BPH and 268 with PC, with a median age of 68 years. We found that SRSF‐1 expression was associated with AR (odds ratio [OR]: 1.66), PSMA (OR: 2.13), Ki‐67 (OR: 5.99), insulin receptor (IR)‐α (OR: 2.38), IR‐β (OR: 3.48), IGF1‐R (OR: 1.53), and microvascular density (MVD) was associated with PSMA (OR: 3.44), Ki‐67 (OR: 2.23), IR‐α (OR: 2.91), IR‐β (OR: 3.02), IGF1‐R (OR: 2.95), and SRSF‐1 (OR: 2.21). In the sub cohort of PC patients, we found that SRSF‐1 expression was associated with AR (OR: 2.34), Ki‐67 (OR: 6.77), IR‐α (OR: 2.7), and MVD (OR: 1.98). At the Kaplan–Meier analysis, SRSF‐1(+) patients had worse 5‐ and 9‐year biochemical recurrence (36% and 6%) respect to SRSF‐1(−) (67% and 7%; p < .01) and similarly MVD(+) patients (44% and 7%) respect to MVD(−) (64% and 8%; p < .01). Restricting the analysis only in patients with PC and diabetes, we found that SRSF‐1(+) was associated with Ki‐67(+) (OR: 8.75; p < .05) and MVD(+) (OR: 7.5; p < .05). CONCLUSIONS: PC exhibits widespread heterogeneity in protein expression. In particular, the expressions of the SRSF‐1 protein and of the MVD are associated with a worse prognosis and in particular with a greater cell proliferation. These results, although preliminary, may offer new future scientific insights with the aim of highlighting possible genetic alterations linked to a greater expression of SRSF‐1 and associated with a worse prognosis. |
format | Online Article Text |
id | pubmed-8362056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83620562021-08-17 SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study) Broggi, Giuseppe Lo Giudice, Arturo Di Mauro, Marina Asmundo, Maria Giovanna Pricoco, Elisabetta Piombino, Eliana Caltabiano, Rosario Morgia, Giuseppe Russo, Giorgio Ivan Prostate Original Articles OBJECTIVE: To study the association between insulin receptors (isoforms α and β), insulin growth factor‐1 (IGF1) and serine/arginine splicing factor 1 (SRSF‐1) in patients with prostate cancer (PC) and diabetes. MATERIALS AND METHODS: We retrospectively analyzed data from 368 patients who underwent surgery for PC or benign prostatic hyperplasia (BPH) between 2010 and 2020 at the Department of Urology, University of Catania. Tissue microarray slides were constructed and they were stained for androgen receptor (AR), insulin receptor‐α and ‐β, IGF1 (IGF1‐R), Ki‐67, and prostate specific membrane antigen (PSMA) expression using validated score. RESULTS: The final cohort was represented by 100 patients with BPH and 268 with PC, with a median age of 68 years. We found that SRSF‐1 expression was associated with AR (odds ratio [OR]: 1.66), PSMA (OR: 2.13), Ki‐67 (OR: 5.99), insulin receptor (IR)‐α (OR: 2.38), IR‐β (OR: 3.48), IGF1‐R (OR: 1.53), and microvascular density (MVD) was associated with PSMA (OR: 3.44), Ki‐67 (OR: 2.23), IR‐α (OR: 2.91), IR‐β (OR: 3.02), IGF1‐R (OR: 2.95), and SRSF‐1 (OR: 2.21). In the sub cohort of PC patients, we found that SRSF‐1 expression was associated with AR (OR: 2.34), Ki‐67 (OR: 6.77), IR‐α (OR: 2.7), and MVD (OR: 1.98). At the Kaplan–Meier analysis, SRSF‐1(+) patients had worse 5‐ and 9‐year biochemical recurrence (36% and 6%) respect to SRSF‐1(−) (67% and 7%; p < .01) and similarly MVD(+) patients (44% and 7%) respect to MVD(−) (64% and 8%; p < .01). Restricting the analysis only in patients with PC and diabetes, we found that SRSF‐1(+) was associated with Ki‐67(+) (OR: 8.75; p < .05) and MVD(+) (OR: 7.5; p < .05). CONCLUSIONS: PC exhibits widespread heterogeneity in protein expression. In particular, the expressions of the SRSF‐1 protein and of the MVD are associated with a worse prognosis and in particular with a greater cell proliferation. These results, although preliminary, may offer new future scientific insights with the aim of highlighting possible genetic alterations linked to a greater expression of SRSF‐1 and associated with a worse prognosis. John Wiley and Sons Inc. 2021-07-01 2021-09-01 /pmc/articles/PMC8362056/ /pubmed/34196424 http://dx.doi.org/10.1002/pros.24185 Text en © 2021 The Authors. The Prostate published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Broggi, Giuseppe Lo Giudice, Arturo Di Mauro, Marina Asmundo, Maria Giovanna Pricoco, Elisabetta Piombino, Eliana Caltabiano, Rosario Morgia, Giuseppe Russo, Giorgio Ivan SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study) |
title | SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study) |
title_full | SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study) |
title_fullStr | SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study) |
title_full_unstemmed | SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study) |
title_short | SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study) |
title_sort | srsf‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (diamond study) |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362056/ https://www.ncbi.nlm.nih.gov/pubmed/34196424 http://dx.doi.org/10.1002/pros.24185 |
work_keys_str_mv | AT broggigiuseppe srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy AT logiudicearturo srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy AT dimauromarina srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy AT asmundomariagiovanna srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy AT pricocoelisabetta srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy AT piombinoeliana srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy AT caltabianorosario srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy AT morgiagiuseppe srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy AT russogiorgioivan srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy |